Capital International Investors
SYRE icon

Capital International Investors’s Spyre Therapeutics SYRE Stock Holding History

Capital International Investors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.8M Sell
955,196
-790,933
-45% -$57.7M 0.02% 305
2026
Q1 		$88.1M Sell
1,746,129
-1,746,412
-50% -$65.8M 0.02% 294
2025
Q4 		$114M Buy
3,492,541
+1,100,000
+46% +$28.7M 0.02% 280
2025
Q3 		$40.1M Hold
2,392,541
– – 0.01% 361
2025
Q2 		$35.8M Hold
2,392,541
– – 0.01% 358
2025
Q1 		$38.6M Buy
+2,392,541
New +$49.8M 0.01% 342

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Capital International Investors's SYRE Position: Q2 2026 in Review

Capital International Investors reduced its Spyre Therapeutics (SYRE) stake by 45% in Q2 2026, selling an estimated $57.7M and leaving 955,196 shares worth $84.8M. The position accounts for 0.02% of the portfolio, ranked #305.

Capital International Investors first reported a position in SYRE in Q1 2025 and has held it in 6 quarters since. The position peaked at $114M in Q4 2025. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Capital International Investors held 955,196 shares of Spyre Therapeutics worth $84.8M as of Q2 2026.
  • Capital International Investors sold 790,933 Spyre Therapeutics shares in Q2 2026, an estimated $57.7M.
  • Spyre Therapeutics made up 0.02% of Capital International Investors's portfolio in Q2 2026, its #305 holding.
  • Capital International Investors first reported a position in Spyre Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Capital International Investors's Spyre Therapeutics position peaked at $114M in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Capital International Investors's 13F filing for Q2 2026, filed 12 Aug 2026.